Incidence of Adverse Effects and Discontinuation Rate between Patients Receiving 250 Micrograms and 500 Micrograms of Roflumilast: A Comparative Study
활용도 Analysis
논문 Analysis
연구자 Analysis
저자
주현수
한덕재
이재하
이진국
제어번호
105925685
학술지명
Tuberculosis and Respiratory Diseases
권호사항
Vol.
81
No.
4
[
2018
]
발행처
대한결핵및호흡기학회
자료유형
학술저널
수록면
299-304
언어
English
출판년도
2018
등재정보
KCI등재
소장기관
강원대학교 춘천캠퍼스 도서관 의학분관
경북대학교 도서관 의학분관
고려대학교 의학도서관
부산대학교 중앙도서관
충남대학교 의학도서관
판매처
'
Incidence of Adverse Effects and Discontinuation Rate between Patients Receiving 250 Micrograms and 500 Micrograms of Roflumilast: A Comparative Study' 의 참고문헌
The preclinical pharmacology of roflumilast: a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease
Standardisation of spirometry
Roflumilast: an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials
Roflumilast in moderate-tosevere chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials
Roflumilast in Asian patients with COPD: a randomized placebo-controlled trial
Roflumilast for the treatment of COPD in an Asian population:a randomized, double-blind, parallel-group study
Roflumilast added to triple therapy in patients with severe COPD: a real life study
Reduction of exacerbations by the PDE4 inhibitor roflumilast: the importance of defining different subsets of patients with COPD
Physiological effects of roflumilast at rest and during exercise in COPD
PDE4: a novel target in the treatment of chronic obstructive pulmonary disease
Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary
Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease
Drug safety evaluation of roflumilast for the treatment of COPD: a metaanalysis
Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic
Application of population pharmacokinetic modeling to explore the impact of alternative roflumilast dosing regimens on tolerability
'
Incidence of Adverse Effects and Discontinuation Rate between Patients Receiving 250 Micrograms and 500 Micrograms of Roflumilast: A Comparative Study'
의 유사주제(
